Daniel Athanazio1, Geoffrey Gotto2, Melissa Shea-Budgell3,4, Asli Yilmaz1, Kiril Trpkov1. 1. Department of Pathology and Laboratory Medicine, Calgary Laboratory Services and University of Calgary, Calgary, Alberta, Canada. 2. Division of Urology, University of Calgary, Calgary, Alberta, Canada. 3. Cancer Strategic Clinical Network, Research Innovation and Analytics, Alberta Health Services, University of Calgary, Calgary, Alberta, Canada. 4. Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
Abstract
AIMS: To evaluate concordance, upgrades and downgrades from biopsy to prostatectomy, and associated clincopathological parameters, using the recently proposed Gleason grade groups/International Society of Urologic Pathology (ISUP) grades. METHODS AND RESULTS: We evaluated 2529 patients who underwent biopsy and prostatectomy in our institution from 2005 to 2014. A global grade group (GR)/Gleason score (GS) was used. Factors associated with GR1/GS ≤6 upgrades and GR2/GS3 + 4 downgrades were analysed by multivariable logistic regression. The final GR/GS was identical with the biopsy GR/GS in 59.3% of cases, with the highest concordance for GR2 and GR5 and lowest for GR4. In GR1-5, identical grades were found in GR: (i) 47.6%, (ii) 73.6%, (iii) 52.8%, (iv) 21.4% and (v) 68.3%, respectively. Final GR was upgraded in 32.3% cases; in GR1-4: (i) 52.4%, (ii) 19.0%, (iii) 16.4% and (iv) 32.9%. Most frequent upgrades occurred from biopsy GR1 to prostatectomy GR2. A final GR downgrade was found in 8.3% cases. For individual GR2-5 the downgrades were found in GR: (i) 7.4%, (ii) 30.8%, (iii) 45.7% and (iv) 31.7%. Upgrades of biopsy GR1 were associated with: age ≥60 years, PSA density ≥0.2, ≥2 positive cores, ≥5% core tissue involvement and perineural invasion [area under receiver operating characteristic (ROC) curve 0.699]. Downgrades of biopsy GR2 correlated inversely with: age ≥60 years, PSA >10 ng/ml and ≥2 positive core (area under ROC curve 0.623). CONCLUSIONS: We found highest concordance for GR2 and GR5 and lowest for GR4. The baseline clinical variables associated with GR1 upgrades and GR2 downgrades may play a role in clinical decision-making.
AIMS: To evaluate concordance, upgrades and downgrades from biopsy to prostatectomy, and associated clincopathological parameters, using the recently proposed Gleason grade groups/International Society of Urologic Pathology (ISUP) grades. METHODS AND RESULTS: We evaluated 2529 patients who underwent biopsy and prostatectomy in our institution from 2005 to 2014. A global grade group (GR)/Gleason score (GS) was used. Factors associated with GR1/GS ≤6 upgrades and GR2/GS3 + 4 downgrades were analysed by multivariable logistic regression. The final GR/GS was identical with the biopsy GR/GS in 59.3% of cases, with the highest concordance for GR2 and GR5 and lowest for GR4. In GR1-5, identical grades were found in GR: (i) 47.6%, (ii) 73.6%, (iii) 52.8%, (iv) 21.4% and (v) 68.3%, respectively. Final GR was upgraded in 32.3% cases; in GR1-4: (i) 52.4%, (ii) 19.0%, (iii) 16.4% and (iv) 32.9%. Most frequent upgrades occurred from biopsy GR1 to prostatectomy GR2. A final GR downgrade was found in 8.3% cases. For individual GR2-5 the downgrades were found in GR: (i) 7.4%, (ii) 30.8%, (iii) 45.7% and (iv) 31.7%. Upgrades of biopsy GR1 were associated with: age ≥60 years, PSA density ≥0.2, ≥2 positive cores, ≥5% core tissue involvement and perineural invasion [area under receiver operating characteristic (ROC) curve 0.699]. Downgrades of biopsy GR2 correlated inversely with: age ≥60 years, PSA >10 ng/ml and ≥2 positive core (area under ROC curve 0.623). CONCLUSIONS: We found highest concordance for GR2 and GR5 and lowest for GR4. The baseline clinical variables associated with GR1 upgrades and GR2 downgrades may play a role in clinical decision-making.
Authors: Brunno C F Sanches; Ana Luiza Lalli; Wilmar Azal Neto; Athanase Billis; Leonardo Oliveira Reis Journal: World J Urol Date: 2018-03-01 Impact factor: 4.226
Authors: Michelle R Downes; John R Srigley; Andrew Loblaw; Nathan Perlis; Sangeet Ghai; Theodorus van der Kwast Journal: Can Urol Assoc J Date: 2022-04 Impact factor: 1.862
Authors: Anne Offermann; Silke Hohensteiner; Christiane Kuempers; Julika Ribbat-Idel; Felix Schneider; Finn Becker; Marie Christine Hupe; Stefan Duensing; Axel S Merseburger; Jutta Kirfel; Markus Reischl; Verena Lubczyk; Rainer Kuefer; Sven Perner Journal: Front Med (Lausanne) Date: 2017-09-29
Authors: Thorgerdur Palsdottir; Tobias Nordström; Markus Aly; Johan Lindberg; Mark Clements; Lars Egevad; Henrik Grönberg; Martin Eklund Journal: PLoS One Date: 2019-06-13 Impact factor: 3.240
Authors: Kerri Beckmann; Michael O'Callaghan; Andrew Vincent; Penelope Cohen; Martin Borg; David Roder; Sue Evans; Jeremy Millar; Kim Moretti Journal: Asian J Urol Date: 2019-03-07
Authors: Geert J L H van Leenders; Theodorus H van der Kwast; David J Grignon; Andrew J Evans; Glen Kristiansen; Charlotte F Kweldam; Geert Litjens; Jesse K McKenney; Jonathan Melamed; Nicholas Mottet; Gladell P Paner; Hemamali Samaratunga; Ivo G Schoots; Jeffry P Simko; Toyonori Tsuzuki; Murali Varma; Anne Y Warren; Thomas M Wheeler; Sean R Williamson; Kenneth A Iczkowski Journal: Am J Surg Pathol Date: 2020-08 Impact factor: 6.298
Authors: Michelle M Kouspou; Jenna E Fong; Nadine Brew; Sarah T F Hsiao; Seanna L Davidson; Peter L Choyke; Tony Crispino; Suneil Jain; Guido W Jenster; Beatrice S Knudsen; Jeremy L Millar; Nicole Mittmann; Charles J Ryan; Bertrand Tombal; Mark Buzza Journal: Nat Rev Urol Date: 2020-07-22 Impact factor: 14.432